Table 5. Proportional Hazards Regression Model High Risk Patients by PSA (n=2193).

Variable		All patients (n=2193)			UH PSA cohort † (n=401)
		OS HR (95% CI)	DM HR (95% CI)	BF HR (95% CI)	OS HR (95% CI)	DM HR (95% CI)	BF HR (95% CI)
PSA	<50 ng/ml ≥50 ng/ml	RL 1.19 (1.02-1.39)	RL 1.51 (1.19-1.92)	RL 1.50 (1.29-1.73)	ns	1.01 (1.01-1.02)	ns
Age	Continuous	1.04 (1.03-1.05)	0.97 (0.96-0.99)	0.97 (0.96-0.98)	1.05 (1.02-1.07)	ns	0.97 (0.95-0.99)
Gleason Score	2-6 7 8-10	RL ns 1.49 (1.27-1.74)	RL 1.38 (1.05-1.82) 2.36 (1.82-3.07)	RL 1.30 (1.13-1.51) 1.51 (1.30-1.76)	RL ns 1.83 (1.27-2.62)	RL ns 2.07 (1.15-3.73)	RL ns 1.41 (1.002-1.99)
T Stage	T1/T2 T3/T4	RL ns	RL 1.49 (1.20-1.85)	RL ns	RL ns	RL 2.07 (1.33-3.20)	RL ns
KPS	70-90 100	RL 0.74 (0.65-0.84)	RL ns	RL ns	RL 0.70 (0.53-0.94)	RL ns	RL ns
Treatment arm	9202: Arm 1 9202: Arm 2 9413: Arm 1 9413: Arm 2 9413: Arm 3 9413: Arm 4	RL ns ns ns 1.32 (1.06-1.65) ns	RL 0.63 (0.49-0.81) 0.61 (0.42-0.89) 0.65 (0.44-0.95) ns 0.57 (0.39-0.84)	RL 0.53 (0.45-0.63) 0.69 (0.56-0.85) ns 0.77 (0.63-0.94) 0.70 (0.57-0.87)	RL ns ns ns 2.42 (1.51-3.88) ns	RL ns ns ns ns ns	RL 0.67 (0.48, 0.93) ns ns ns ns

^†continuous PSA variable, OS=overall survival; DMFS=distant metastases; BF=biochemical failure; RL=reference level; ns=not significant; T=tumor; PSA=prostate specific antigen; KPS=Karnofsky performance status; HR= Hazard ratio; CI=Confidence interval; ns=statistically non-significant